Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL

Clinical Biochemistry

Volumn 39, Issue 4, 2006, Pages 363-366

  Eskicorapci, Saadettin Yilmaz ^a   Özkara, H Asuman ^a   Önder, Evren ^a   Akdogan, Bulent ^a   Erkan, Ilhan ^a   Ciliv, Gonenc ^a   Ozen, Haluk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Prostate specific antigen; Prostatic neoplasms; Ribonuclease

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RIBONUCLEASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BLOOD LEVEL;

CASE-CONTROL STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RIBONUCLEASES;

EID: 33646095242     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2005.11.020     Document Type: Article

References (19)

1. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274 (1996) 1371-1374
2. Gonzalzo M.L., and Isaacs W.B. Molecular pathways to prostate cancer. J. Urol. 170 (2003) 2444-2448
3. Rokman A., Ikonen T., Seppala E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70 (2002) 1299-1303
4. Mowbray J.F. Immunosuppresive action of ribonucleases. J. Clin. Pathol. 20 (1967) 499-501
5. Erkan I., Ciliv G., and Remzi D. Effects of diethylstilbestrol diphosphate on serum and tissue ribonuclease levels in prostatic carcinoma. J. Surg. Oncol. 21 (1982) 65-70
6. Chu T.M. Serum acid phosphohydrolase (phosphatase) and ribonuclease in diagnosis of prostatic cancer. Antibiot. Chemother. 22 (1978) 98-101
7. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-What we have learned and where we are going. J. Urol. 162 (1999) 293-299
8. Djavan B., Remzi M., Zlotta A.R., et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 60 4A (2002) 4-9
9. Balk S.P., Yoo-Joung K., and Babley G.J. Biology of prostate specific antigen. J. Clin. Oncol. 21 2 (2003) 383-389
10. Sozen S., Eskicorapci S., Kupeli B., et al. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/mL: results of a prospective multicenter study. Eur. Urol. 47 3 (2005) 302-307
11. Eskicorapci S.Y., Baydar D.E., Akbal C., et al. An extended 10-core transrectal ultrasonography-guided prostate biopsy protocol improves the detection of prostate cancer. Eur. Urol. 45 4 (2004) 444-449
12. Chretien P.B., Matthews W., and Twomey L. Serum ribonucleases in cancer: relation to tumor histology. Cancer 31 (1973) 175-179
13. Carter H.B., Epstein J.I., Chan D.W., Fozard J.L., and Pearson J.D. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277 (1997) 1456-1560
14. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging. Urology 56 (2000) 255-258
15. Stamey T.A., and Yemoto C.E. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J. Urol. 163 (2000) 119-123
16. Sun L., Gancarczyk K., Paquette E.L., et al. Introduction to department of defence center for prostate disease research multicenter national prostate cancer database, and analysis of changes in the PSA-era. Urol. Oncol. 6 (2001) 203-206
17. Haese A., Dworschack R.T., and Partin A.W. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng/mL range does substantially increase the number of biopsies needed detect clinically significant prostate cancer compared to the 4 to 10 ng/mL range. J. Urol. 168 (2002) 504-508
18. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA-levels are 2.51-4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 (1999) 220-225
19. Eskicorapci S.Y., Guliyev F., Akdogan B., Dogan H.S., Ergen A., and Ozen H. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J. Urol. 173 5 (2005) 1536-1540